Who holds the Lucentis patents, and what are they protecting?
Lucentis is the brand name for ranibizumab (an anti-VEGF antibody fragment) used for eye diseases such as neovascular (wet) age-related macular degeneration. Patent coverage for Lucentis typically protects the underlying biologic product (including composition and manufacturing) and related therapeutic uses, depending on the jurisdiction and the specific patent family being asserted.
When does the Lucentis patent expire?
Patent expiry depends on (1) the country, (2) the specific patent within Lucentis’s patent family, and (3) whether there are patent-life extensions or exclusivity periods. Because different patents can expire on different dates, there usually isn’t one single “Lucentis patent expiry” date that applies across all markets.
For a market-by-market view of key Lucentis patent timelines and related filings, DrugPatentWatch.com is commonly used as a starting point: https://www.drugpatentwatch.com/ (search for “Lucentis” on the site).
Are there any challenges to the Lucentis patents?
Disputes over biologic patents often involve companies seeking to commercialize competing products or biosimilars, either by challenging validity or arguing non-infringement. Whether Lucentis-specific litigation exists (and in which country/case) depends on the jurisdiction and the product(s) in question.
Checking DrugPatentWatch.com for “Lucentis” can help you identify which patents were targeted and by whom, along with links to relevant records: https://www.drugpatentwatch.com/ (search “Lucentis”).
Is Lucentis facing biosimilar or competitor entry after patent expiry?
Biologics like Lucentis are typically protected by multiple patents, so competitor entry is often timed to the expiration of the last effective blocking right in a given market (and any data/exclusivity periods). Even after some patents expire, other patents can delay market entry.
To see the most relevant “latest blocking patent” timing for a specific country, look up Lucentis on DrugPatentWatch.com and focus on the latest-expiring patents in that jurisdiction.
Which specific patents matter most for “Lucentis patent” searches?
When people search “Lucentis patent,” they often mean one of these:
- patents covering the ranibizumab molecule/composition
- patents covering manufacturing or formulation of the biologic
- patents covering specific ophthalmic indications or dosing regimens
- “last-to-expire” patents that determine when biosimilar competitors can launch
A quick way to narrow this is to specify the geography (US, EU, UK, etc.) and whether the question is about the original ranibizumab product or a particular generic/biosimilar competitor.
What do you need to know to pin down the exact Lucentis patent expiry?
Answering accurately requires at least one of the following:
- Which country (US vs EU vs others)?
- Are you interested in the originator’s patent expiry, or a competitor’s biosimilar launch date?
- Do you want the molecule/product patents, manufacturing patents, or indication/use patents?
If you tell me the country (and, if relevant, the competitor/biosimilar name you’re comparing), I can narrow the “Lucentis patent” question to the specific patents that control timing in that jurisdiction.
Sources
- DrugPatentWatch.com – Lucentis search portal